AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31915996 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin-warfarin (enox-warfarin)
Number of subjects: 2199
Study 31670578 — intervention group
Group type: EXPERIMENTAL
Intervention: ZTE-MRI
Number of subjects: 20
Study 31670578 — intervention group
Group type: COMPARATOR
Intervention: CBCT
Number of subjects: 20
Study 25819354 — intervention group
Group type: EXPERIMENTAL
Intervention: ossein-hydroxyapatite complex (OHC) 1,660 mg/day
Number of subjects: 74
Study 25819354 — intervention group
Group type: COMPARATOR
Intervention: calcium carbonate (CC) 1,200 mg/day
Number of subjects: 74
Study 25819354 — intervention group
Group type: EXPERIMENTAL
Intervention: ossein-hydroxyapatite complex (OHC)
Number of subjects: 74
Study 25819354 — intervention group
Group type: COMPARATOR
Intervention: calcium carbonate (CC)
Number of subjects: 74
Study 24786946 — intervention group
Group type: EXPERIMENTAL
Intervention: Build Better Bones With Exercise (B3E) intervention including exercise and behavioral counseling, delivered by a physical therapist in 6 home visits over 8 months, and monthly calls; participants are to exercise ≥3 times weekly.
Number of subjects: 160
Study 24786946 — intervention group
Group type: COMPARATOR
Intervention: Attentional control group receiving equal attention.
Number of subjects: 160
Study 21298494 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin and paclitaxel (ET)
Number of subjects: 287
Study 21298494 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin, paclitaxel, and capecitabine (TEX)
Number of subjects: 287
Study 19385964 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Aids for Mode of next Delivery
Number of subjects: 30
Study 17565838 — intervention group
Group type: EXPERIMENTAL
Intervention: In situ coronary venous arterialization (ICVA) during CABG
Number of subjects: 64
Study 17565838 — intervention group
Group type: COMPARATOR
Intervention: Conventional CABG only (control group)
Number of subjects: 64
Study 15382799 — intervention group
Group type: EXPERIMENTAL
Intervention: Swallowing intervention
Number of subjects: 79
Study 12903226 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-intervention nursing caregiving environment (RINCE)
Number of subjects: 10
Study 12903226 — intervention group
Group type: COMPARATOR
Intervention: Control bed (standard RW with Plexiglas hood)
Number of subjects: 10
Study 10386528 — intervention group
Group type: EXPERIMENTAL
Intervention: New antiepileptic drugs (AEDs)
Number of subjects: 0
Study 10386528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8600188 — intervention group
Group type: COMPARATOR
Intervention: Sorbitol gum (9.0 g/day)
Number of subjects: 1277
Study 8600188 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% xylitol pellet gum
Number of subjects: 1277
Study 8600188 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol-sorbitol mixtures
Number of subjects: 1277
Study 8600188 — intervention group
Group type: COMPARATOR
Intervention: Sucrose gum
Number of subjects: 1277
Study 2469708 — intervention group
Group type: EXPERIMENTAL
Intervention: cetirizine, 20 mg
Number of subjects: 10
Study 2469708 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 1096218 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (9 mg/day)
Number of subjects: 8
Study 1096218 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine (225 mg/day)
Number of subjects: 8
Study 31049747 — intervention group
Group type: EXPERIMENTAL
Intervention: New simple risk score (Chen score)
Number of subjects: 1157
Study 31049747 — intervention group
Group type: COMPARATOR
Intervention: Classical Mehran or ACEF risk score
Number of subjects: 1157
Study 28443283 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclavian dialysis catheters
Number of subjects: 1016
Study 28443283 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal jugular dialysis catheters
Number of subjects: 1016
Study 28443283 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral dialysis catheters
Number of subjects: 1016
Study 28443283 — intervention group
Group type: COMPARATOR
Intervention: All catheter locations
Number of subjects: 1016
Study 26303014 — intervention group
Group type: EXPERIMENTAL
Intervention: Short course radiotherapy (RT) alone (4Gy/#/day for 5 days)
Number of subjects: 111
Study 26303014 — intervention group
Group type: EXPERIMENTAL
Intervention: Short course concurrent palliative chemotherapy (cisplatin at 6mg/m2/day IV bolus for 5 days) plus radiotherapy (RT as arm A)
Number of subjects: 111
Study 23442280 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Stretching (DS)
Number of subjects: 11
Study 23442280 — intervention group
Group type: EXPERIMENTAL
Intervention: Static Stretching (SS)
Number of subjects: 11
Study 23442280 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 11
Study 21504334 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin administration alone or with a concomitant drug
Number of subjects: 0
Study 18718725 — intervention group
Group type: EXPERIMENTAL
Intervention: SIB-IMRT
Number of subjects: 78
Study 18718725 — intervention group
Group type: COMPARATOR
Intervention: SEQ
Number of subjects: 78
Study 16562630 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant stimulation
Number of subjects: 7
Study 16562630 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized frequency (mean 40 Hz)
Number of subjects: 7
Study 16562630 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized current amplitude
Number of subjects: 7
Study 16562630 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized pulsewidth (mean 250 micros)
Number of subjects: 7
Study 16562630 — intervention group
Group type: EXPERIMENTAL
Intervention: All modes of stimulation
Number of subjects: 7
Study 16562630 — intervention group
Group type: EXPERIMENTAL
Intervention: Stochastic modulation of stimulation parameters
Number of subjects: 7
Study 16562630 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum force measurements
Number of subjects: 7
Study 16562630 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-min rest period between stimulation trials
Number of subjects: 7
Study 15050083 — intervention group
Group type: EXPERIMENTAL
Intervention: Harm Reduction Group (HRG) - 12-session intervention
Number of subjects: 220
Study 15050083 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC) - 2 hours of counseling per month and a single-session risk reduction intervention
Number of subjects: 220
Study 11770479 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐Regulatory Prevention and Relationship Enhancement Program (Self‐PREP)
Number of subjects: 83
Study 11770479 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 83
Study 9250098 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training for 5 weeks (n = 22)
Number of subjects: 44
Study 9250098 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 22)
Number of subjects: 44
Study 8186781 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alfentanil-midazolam anesthesia
Number of subjects: 65
Study 8186781 — intervention group
Group type: COMPARATOR
Intervention: Spinal anesthesia
Number of subjects: 65
Study 2660754 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam (1 gr. IM daily for 7 days)
Number of subjects: 0
Study 2660754 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin (100 mgr. IM q 12 h for 7 days)
Number of subjects: 0
Study 30953731 — intervention group
Group type: EXPERIMENTAL
Intervention: TeachTown: Basics
Number of subjects: 154
Study 30953731 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (waitlist control)
Number of subjects: 154
Study 31547752 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone
Number of subjects: 38
Study 31547752 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 28679400 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity coaching system alongside a home-based exercise program
Number of subjects: 110
Study 28679400 — intervention group
Group type: COMPARATOR
Intervention: Home-based exercise program
Number of subjects: 110
Study 25348833 — intervention group
Group type: EXPERIMENTAL
Intervention: Measured setting formulas for RMV
Number of subjects: 0
Study 25348833 — intervention group
Group type: EXPERIMENTAL
Intervention: Measured setting formulas for BV
Number of subjects: 0
Study 25348833 — intervention group
Group type: COMPARATOR
Intervention: Standard formulas for RMV
Number of subjects: 0
Study 25348833 — intervention group
Group type: COMPARATOR
Intervention: Standard formulas for BV
Number of subjects: 0
Study 23442371 — intervention group
Group type: EXPERIMENTAL
Intervention: C1q‐APN
Number of subjects: 117
Study 23442371 — intervention group
Group type: EXPERIMENTAL
Intervention: C1q‐APN/C1q ratio
Number of subjects: 117
Study 23442371 — intervention group
Group type: EXPERIMENTAL
Intervention: C1q‐APN/Total‐APN ratio
Number of subjects: 117
Study 20936499 — intervention group
Group type: EXPERIMENTAL
Intervention: High Youth and Mother group
Number of subjects: 938
Study 20936499 — intervention group
Group type: COMPARATOR
Intervention: Low Youth/High Mother group
Number of subjects: 938
Study 19749496 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg/day
Number of subjects: 40
Study 19749496 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day
Number of subjects: 40
Study 19749496 — intervention group
Group type: EXPERIMENTAL
Intervention: Other statins (Simvastatin 40 mg/day, Pravastatin 40 mg/day)
Number of subjects: 40
Study 16802360 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (1,000 mg) and vitamin D (400 IU) supplementation
Number of subjects: 198
Study 16802360 — intervention group
Group type: COMPARATOR
Intervention: Placebo and vitamin D (400 IU)
Number of subjects: 198
Study 14627926 — intervention group
Group type: EXPERIMENTAL
Intervention: DeLorme technique
Number of subjects: 50
Study 14627926 — intervention group
Group type: COMPARATOR
Intervention: Oxford technique
Number of subjects: 50
Study 10783648 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine 0.33% (verum)
Number of subjects: 56
Study 10783648 — intervention group
Group type: COMPARATOR
Intervention: NaCl 0.9% (placebo)
Number of subjects: 56
Study 9305226 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihistamine-treated group
Number of subjects: 99
Study 9305226 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy group
Number of subjects: 99
Study 9305226 — intervention group
Group type: COMPARATOR
Intervention: Nonatopic group
Number of subjects: 99
Study 8349365 — intervention group
Group type: EXPERIMENTAL
Intervention: Xamoterol
Number of subjects: 10
Study 3303976 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine chewing gum; two individual consultations
Number of subjects: 334
Study 3303976 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 334
Study 29307660 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol (2 μg/day for 12 weeks)
Number of subjects: 88
Study 29307660 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo for 12 weeks)
Number of subjects: 88
Study 29092731 — intervention group
Group type: EXPERIMENTAL
Intervention: Single CER intact capsule (30 mg)
Number of subjects: 32
Study 29092731 — intervention group
Group type: COMPARATOR
Intervention: Single CER capsule contents sprinkled over applesauce (15 mL)
Number of subjects: 32
Study 24136051 — intervention group
Group type: EXPERIMENTAL
Intervention: Zero-profile implant
Number of subjects: 46
Study 24136051 — intervention group
Group type: COMPARATOR
Intervention: Anterior plate and cage (control group)
Number of subjects: 46
Study 23000961 — intervention group
Group type: EXPERIMENTAL
Intervention: lipo-prostaglandin E1 (lipo-PGE1)
Number of subjects: 286
Study 23000961 — intervention group
Group type: COMPARATOR
Intervention: standard treatment
Number of subjects: 286
Study 21939867 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Number of subjects: 355
Study 21939867 — intervention group
Group type: COMPARATOR
Intervention: Structured brief advice
Number of subjects: 355
Study 19100931 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium (0.3 mg kg(‐1) IV)
Number of subjects: 13
Study 19100931 — intervention group
Group type: COMPARATOR
Intervention: Succinylcholine (1 mg kg(‐1) IV)
Number of subjects: 13
Study 16785771 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological therapy (PCT)
Number of subjects: 71
Study 16785771 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavior therapy (CBT)
Number of subjects: 71
Study 16785771 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy
Number of subjects: 71
Study 16785771 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 12695418 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (100 mg)
Number of subjects: 20
Study 12695418 — intervention group
Group type: COMPARATOR
Intervention: NG‐monomethyl‐L‐arginine (nitric oxide synthase inhibitor)
Number of subjects: 20
Study 11120730 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Number of subjects: 7
Study 11120730 — intervention group
Group type: COMPARATOR
Intervention: Sham manipulation (control)
Number of subjects: 7
Study 8925581 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 674
Study 8925581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 674
Study 8925581 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (nonischemic etiology)
Number of subjects: 674
Study 8925581 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (ischemic group)
Number of subjects: 674
Study 1514723 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized magnesium sulfate (3 mL, 268 mmol/L, pH 6.4)
Number of subjects: 10
Study 1514723 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized albuterol (2.5 mg in 3 mL saline)
Number of subjects: 10
Study 1514723 — intervention group
Group type: COMPARATOR
Intervention: Nebulized normal saline (3 mL)
Number of subjects: 10
Study 6653081 — intervention group
Group type: EXPERIMENTAL
Intervention: Orientation statement at the time the appointment was made
Number of subjects: 0
Study 6653081 — intervention group
Group type: EXPERIMENTAL
Intervention: Orientation statement plus phone prompt
Number of subjects: 0
Study 6653081 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone prompt only
Number of subjects: 0
Study 6653081 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 31235380 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention studies (3‐6 months)
Number of subjects: 143
Study 29699885 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD registry (285 patients)
Number of subjects: 746
Study 29699885 — intervention group
Group type: COMPARATOR
Intervention: Usual-care registry (461 patients)
Number of subjects: 746
Study 26720847 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 IU/kg intravenous unfractionated heparin (UFH) bolus
Number of subjects: 72
Study 26720847 — intervention group
Group type: COMPARATOR
Intervention: In-vitro UFH spiking
Number of subjects: 72
Study 24467802 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training, e-coaching, lunch walking routes, and fruit (intervention group)
Number of subjects: 257
Study 24467802 — intervention group
Group type: COMPARATOR
Intervention: Control group received information on existing lifestyle behavior-related facilities (control group)
Number of subjects: 257
Study 24467802 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training (intervention group)
Number of subjects: 257
Study 23377601 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental health program with mothers' involvement (n=26)
Number of subjects: 50
Study 23377601 — intervention group
Group type: COMPARATOR
Intervention: Brochures providing knowledge related to dental health (Control group, n=24)
Number of subjects: 50
Study 20091486 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium diet for 6 weeks
Number of subjects: 171
Study 20091486 — intervention group
Group type: COMPARATOR
Intervention: Normal sodium intake (control group)
Number of subjects: 171
Study 17384847 — intervention group
Group type: EXPERIMENTAL
Intervention: G1 Prime & Bond 2.1
Number of subjects: 30
Study 17384847 — intervention group
Group type: EXPERIMENTAL
Intervention: G2 Clearfil SE Bond
Number of subjects: 30
Study 17384847 — intervention group
Group type: EXPERIMENTAL
Intervention: G3 One Up Bond F
Number of subjects: 30
Study 15943219 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 10 mg/day
Number of subjects: 20
Study 15943219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11865170 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 10 mg tid
Number of subjects: 30
Study 11865170 — intervention group
Group type: COMPARATOR
Intervention: Control group (less severe hyperemesis, no steroid therapy)
Number of subjects: 30
Study 10199874 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (6.7 g/min for 45 minutes)
Number of subjects: 25
Study 10199874 — intervention group
Group type: EXPERIMENTAL
Intervention: DIP (intravenous dipyridamole)
Number of subjects: 25
Study 10199874 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary flow reserve
Number of subjects: 25
Study 8786246 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine A (150 mg twice daily) - Neoral
Number of subjects: 37
Study 8786246 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine A (150 mg twice daily) - Sandimmune
Number of subjects: 37
Study 8786246 — intervention group
Group type: COMPARATOR
Intervention: Crossover analysis - Neoral vs Sandimmune
Number of subjects: 37
Study 8786246 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 37
Study 2083807 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 French catheter
Number of subjects: 60
Study 2083807 — intervention group
Group type: COMPARATOR
Intervention: 8 French catheter
Number of subjects: 60
Study 2083807 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 6996935 — intervention group
Group type: EXPERIMENTAL
Intervention: guanabenz (mean dose 24 mg daily)
Number of subjects: 29
Study 31419023 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured ostomy care training (oral and practical training, question and answer session, and an ostomy information booklet)
Number of subjects: 60
Study 31419023 — intervention group
Group type: COMPARATOR
Intervention: Routine ostomy care (control group)
Number of subjects: 60
Study 27749608 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser acupuncture (LA)
Number of subjects: 69
Study 27749608 — intervention group
Group type: COMPARATOR
Intervention: Control (sham points)
Number of subjects: 69
Study 26775477 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood activating wind dissipating acupuncture (BAWDA) for 6 weeks (30 sessions)
Number of subjects: 60
Study 26775477 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood activating wind dissipating acupuncture (BAWDA)
Number of subjects: 60
Study 26775477 — intervention group
Group type: COMPARATOR
Intervention: Control group (lifestyle intervention only)
Number of subjects: 60
Study 23942276 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness‐Oriented Recovery Enhancement (MORE) intervention
Number of subjects: 67
Study 23942276 — intervention group
Group type: COMPARATOR
Intervention: Social support group intervention
Number of subjects: 67
Study 20352383 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery (MIS)
Number of subjects: 120
Study 20352383 — intervention group
Group type: COMPARATOR
Intervention: Classic approach (CLASS)
Number of subjects: 120
Study 19577150 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-phase treatment with bionator
Number of subjects: 260
Study 19577150 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-phase treatment with headgear/biteplane
Number of subjects: 260
Study 19577150 — intervention group
Group type: COMPARATOR
Intervention: Observation group
Number of subjects: 260
Study 18046226 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of high-dose triamcinolone acetonide (20-25 mg)
Number of subjects: 39
Study 18046226 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal injection of dexamethasone (500 mug)
Number of subjects: 39
Study 15501952 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (75 mg/m2 i.v. day 1) and capecitabine (1000 mg/m2 orally twice daily days 2‐15) for four cycles (Dose A)
Number of subjects: 30
Study 15501952 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (60 mg/m2 i.v. day 1) and capecitabine (937.5 mg/m2 orally twice daily days 2‐15) for four cycles (Dose B)
Number of subjects: 30
Study 11384089 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine as first-line treatment for metastatic breast cancer
Number of subjects: 0
Study 11384089 — intervention group
Group type: COMPARATOR
Intervention: Low-dose CMF (control group)
Number of subjects: 0
Study 11384089 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine in paclitaxel-refractory patients
Number of subjects: 0
Study 11384089 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine in anthracycline-refractory patients
Number of subjects: 0
Study 9021428 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A (450 mg propafenone)
Number of subjects: 105
Study 9021428 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen B (600 mg propafenone)
Number of subjects: 105
Study 9021428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 9021428 — intervention group
Group type: COMPARATOR
Intervention: Regimen A vs Placebo
Number of subjects: 105
Study 9021428 — intervention group
Group type: COMPARATOR
Intervention: Regimen B vs Placebo
Number of subjects: 105
Study 9021428 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A vs Regimen B
Number of subjects: 105
Study 9021428 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean ventricular rate reduction
Number of subjects: 105
Study 8199787 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtypes of major depression classified by longitudinal course
Number of subjects: 0
Study 8199787 — intervention group
Group type: EXPERIMENTAL
Intervention: Indicators of validity for recurrent depression
Number of subjects: 0
Study 3148366 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally administered thyrotropin-releasing hormone (TRH) (40 mg/day for 10 days)
Number of subjects: 11
Study 3148366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11